Voiding urosonography with ultrasound contrast agents for the diagnosis of vesicoureteric reflux in children
- First online:
Voiding urosonography (VUS) encompasses examination of the urinary tract with intravesical administration of US contrast agent (UCA) for diagnosis of vesicoureteric reflux (VUR). The real breakthrough for US examination of VUR came with the availability of stabilized UCAs in the mid-1990s. This article presents a comprehensive review of various procedural aspects of VUS. Different US modalities are available for detecting the echogenic microbubbles: fundamental mode, colour Doppler US, harmonic imaging and dedicated contrast imaging with multiple display options. The reflux is graded (1 to 5) in a similar manner to the system used in voiding cystourethrography (VCUG). The most commonly used UCA for VUS, Levovist, is galactose-based and contains air-filled microbubbles. The recommended concentration is 300 mg/ml at a dose of 5–10%, or less than 5%, of the bladder filling volume when using fundamental or harmonic imaging modes, respectively. There are preliminary reports of VUS using a second-generation UCA, SonoVue. Here the UCA volume is less than 1% of the bladder filling volume. There is no specific contraindication to intravesical administration of UCA. The safety profile of intravesical Levovist is very high with no reports of side effects over a decade of use in VUS.
KeywordsVoiding urosonography Ultrasound contrast agent Vesicoureteric reflux
Diagnostic imaging for vesicoureteric reflux (VUR) is a common procedure in children. Currently, three modalities are available for reflux diagnosis, namely voiding cystourethrography (VCUG), radionuclide cystography (RNC) and voiding urosonography (VUS). The last of these is carried out using US in combination with intravesical administration of US contrast agent (UCA). This allows the use of ionizing radiation to be avoided, which is not the case in RNC and VCUG. However, in VCUG a marked reduction in radiation dose has been achieved with the introduction of digital pulsed fluoroscopy.
The first attempts at the implementation of US for the diagnosis of VUR began in the mid-1970s. A comprehensive account of the evolution of this undertaking over the subsequent two decades has been presented by Darge . The indirect methods for reflux diagnosis were based on US of the urinary tract, without administration of any kind of substance into the bladder. These included depicting various sonomorphological changes of the urinary tract as a result of VUR, detecting newly appearing or an increase in existing ureteral or pelvicalyceal dilatation during voiding and assessing ureteric jet changes with duplex and colour Doppler US. The direct means used to diagnose VUR required instilling different substances intravesically. The most frequently administered fluid was physiological saline solution. Ballooning of the renal pelvis during the filling of the bladder was the criterion for diagnosis of VUR. Application of air bubbles, by shaking the normal saline before administration or adding carbon dioxide, were also tried. US studies were also carried out, in which the empty bladder was solely filled with air. In addition to low diagnostic accuracy, all the above methods had major procedural drawbacks making them impractical for widespread integration into routine imaging.
The intravesical use of a UCA consisting of sonicated albumin (Albunex; Molecular Biosystems, San Diego, Calif.) for VUS in a child was first reported in 1994 . Another UCA used in the past was Echovist (Schering, Berlin, Germany), which is composed of galactose with incorporated microbubbles . Its very short imaging window of approximately 5 min, however, prevented its routine application. The breakthrough in US diagnosis of VUR in children came about the mid-1990s with the availability of UCAs containing stabilized microbubbles. Levovist (Levograf, Schering Spain, Madrid, Spain; SHU-508-A, Schering, Berlin, Germany) was the first such UCA to become available for clinical use in Europe. This opened the door for rapid development of VUS and its introduction as part of the routine diagnostic imaging option of VUR.
A number of different names and acronyms have been put forward to denote US examination for the diagnosis of VUR using intravesical UCAs. These include simply “sonography/ultrasound” [4–6], “reflux sonography” , “cystography” [8–10], “cystosonography” [11–15], “cystourethrosonography”  and “urosonography” [17–23]. They are more often used in combination with one or more of the following terms: “echo-enhanced”, “contrast-enhanced” and “voiding”. Depending on the US technique employed further descriptions such as “colour Doppler US” or “harmonic imaging” are added. The most widely applied name “voiding urosonography” with the abbreviation “VUS” was proposed for the first time in 2000 . The selection of this particular designation was based on careful consideration of various factors. The prefix “uro-” is used to denote the bladder, ureters and kidneys. “Sonography” was chosen rather than “ultrasonography” as it is a shorter form. Thus “urosonography” correctly describes the fact that in this examination US of the bladder, ureters and kidneys takes place independent of the absence or presence of VUR. “Voiding” was selected instead of “micturating” as it is used more commonly in the medical literature. Despite the fact that for VCUG x-ray contrast agent is necessary, this is not directly added to the name VCUG in the form of, for example, contrast-VCUG. Likewise, the terms “contrast” or “echo-enhanced” were not added by default to the basic term “voiding urosonography”. The abbreviation “VUS” is not only similar to the most common acronym used for the radiological reflux examination, namely VCUG, but had also not been used in the medical literature to denote something else . For the sake of minimizing the confusion of names and facilitating communication, literature search and procedural standardization, the use of one name for the same procedure, “voiding urosonography” (“VUS”) is recommended.
This article is part I of a comprehensive review of all currently available literature on VUS and prepares the ground for objective evaluation and decision-making. In this part (part I) a detailed procedural description is presented, including discussion of the pros and cons of the various examination steps and imaging modalities for VUS. The measures undertaken to optimize VUS are elaborated. Furthermore, studies dealing with adverse events of intravesical administration of UCAs are reviewed. In part II a review of comparative studies between VUS and RNC/VCUG is presented .
US contrast agent
The most widely used UCA for VUS is Levovist. This first-generation UCA was introduced for intravenous (IV) use in the mid-1990s and from 1999 started to obtain approval for intravesical application in children successively in 13 European countries and Australia. Levovist consists of dry granules made of galactose and palmitic acid . The granules easily disintegrate into microparticles upon preparation. They form porous structures, which are necessary for the formation of bubbles. Gas bubbles are formed within the pores during suspension of the granules, while dissolution of the galactose particles begins simultaneously. The Levovist bubble is a microbubble of air—65% nitrogen and 35% oxygen—stabilized by palmitic acid. One gram of Levovist granules contains 999 mg d-galactose and 1 mg palmitic acid. The concentrations of microbubbles in freshly prepared batches (300 mg/ml) are within the range of approximately 1–2×108 microbubbles per millilitre of suspension. The Levovist suspension should always be freshly prepared prior to intravesical administration. The steps of preparation, as outlined by the manufacturer, must be strictly adhered to in order to avoid any reduction of contrast enhancement due to improper handling . The administration of freshly prepared UCA has to be carried out within 30 min .
The recommended concentration of Levovist for VUS is 300 mg/ml . This concentration has been used for VUS in most studies. A concentration of 200 mg/ml seems to result in faster dissipation of microbubbles, as found in in-vitro experiments (unpublished data). In only three studies has a concentration of 200 mg/ml been used [13, 15, 30]. Bosio initially used this concentration, but later changed to the higher one as the conspicuity of refluxing microbubbles in fundamental mode was inadequate . In another study in adults with transplanted kidneys this concentration in combination with an increased volume, i.e. 10–15% of bladder filling, was used . The combination of colour Doppler US with the burst technique administering 200 mg/ml selectively in infants has been reported, but the results using just this concentration were not analyzed separately . The utilization of the higher concentration of 400 mg/ml has only been reported once without any additional advantages being mentioned . Probably, the disadvantage would be an increase in UCA volume leading to an unwarranted increase in cost.
The volume of UCA administered has been rather variable. Some have applied a fixed dose for all, independent of the patient’s age, weight and bladder volume [4, 5]. In one study the volume was calculated in terms of body weight . In most studies the volume of bladder filling is taken as the decisive factor [1, 12, 28]. This is very logical when considering intravesical administration of UCA and contrast enhancement of bladder content. It is possible to directly measure the bladder volume using the formula for an ellipse (length×width×height×0.5], note the total volume of normal saline administered in the bladder and also calculate in a simple way the maximum bladder capacity: volume in millilitres = (age in years +2)×30 . Furthermore, using the bladder volume for calculation of UCA dose makes comparison between studies much easier.
Nakamura et al.  carried out simultaneously VCUG and VUS in 56 children. The fundamental (i.e. conventional) imaging modality was used for VUS. They initially administered Levovist into an almost empty bladder followed by continuous infusion of the radiographic contrast agent. They simultaneously monitored the appearance of reflux during VUS, relating it to the concentration of the UCA in the bladder. The concentration of UCA in the bladder at one point in time ranged form 1.8% to 23%. All false-negative results in the VUS were associated with a Levovist volume of <5% of the total bladder filling. Thus a volume of UCA between 5% and 10% of the bladder filling is required when performing VUS using fundamental imaging. As there is a clear correlation between the experience of the sonographer and the sensitivity of VUS, it is advisable for beginners to start with the highest recommended volume of 10% and with increasing experience to reduce the amount, but without going below 5% of the bladder filling when using fundamental imaging. It seems possible to reduce the UCA volume when adding colour Doppler US . There is clear evidence that when using harmonic imaging, 5% or less of UCA with respect to the bladder filling will suffice [18, 33]. Preliminary experience with dedicated contrast imaging modalities such as cadence agent detection imaging (ADI) (Acuson; Siemens, Mountain View, Calif.) point to the potential of further dose reduction .
UCAs were primarily developed for IV use and, consequently, preclinical studies were aimed at elucidating problems that could potentially have been encountered during administration via this route. Intravesical use is different and has its own peculiarities one must be aware of. An in-vitro study was carried out with Levovist to measure how variations in US machine setting, transducer choice, mode of application and bladder content may affect the microbubbles . The effects of power output, transducer frequency and injection rate were found to be comparable to those during IV administration. The physicochemical properties of particular relevance for intravesical use are described below.
Interaction with normal saline solution
Unlike in VCUG and direct RNC, normal saline plays an important role in VUS. It is the actual bladder filling medium in which the microbubbles are injected. In an in-vitro study the median contrast duration when the UCA was mixed with normal saline solution from glass containers was 30 s, whereas when the same UCA was added to normal saline solution from a plastic container the median contrast duration increased to 11 min . None of the plastic containers were sealed under vacuum. In contrast, most of the glass containers were sealed under vacuum. The mean pO2 of the normal saline solutions from vacuum-sealed containers was found to be 50% less than the pO2 of the normal saline solutions from plastic containers. The air-filled microbubbles of Levovist are permeable to air, and gas is exchanged with the atmosphere until equilibrium is reached . Thus, in normal saline solution with low air saturation the microbubbles tend to collapse promptly . Collapse of the microbubbles means that echo enhancers are not available. In practice, the use of normal saline solution from plastic containers is preferred.
Interaction with urine
Contrast duration of the UCA has been found to be more than four times longer in urine than in normal saline. It has been shown that simply adding urea to buffer the solution significantly increases contrast duration . It is postulated that urea affects the bonding between water molecules and facilitates the formation of more microbubbles. Thus, having some urine in the bladder when performing VUS actually has a positive effect on imaging.
Ascent of microbubbles in the ureter
Once reflux of microbubbles takes place from the bladder into the distal ureter, the question as to whether the microbubbles can ascend passively to the proximal ureter and renal pelvis while the refluxed fluid stays in the distal ureter has been raised . Given constancy of gravity, the density difference between gas and fluid and the viscosity of fluid, the velocity of ascent is proportional to the square of the microbubble radius. The typical microbubble radius of Levovist is 1–2.5 μm. Calculation of velocity of ascent indicates that for all practical purposes passive ascent can be excluded. Furthermore, in an in-vitro simulation of VUS with a set-up imitating the worst-case scenario (90°, glass tube (no adsorption), constant stirring of fluid suspension, and absence of counter-flow) the possibility of passive ascent was evaluated using an ultraviolet spectrometer for the detection of microbubbles. The result of this experiment was also negative. These findings suggest that the microbubbles in the ureter do not ascend passively and that reflux pressure is necessary for propagation, particularly in vivo with a constant counter-flow of urine from the renal pelvis to the bladder.
VUS entails four major basic steps: (1) scan of the urinary tract before contrast agent administration, (2) intravesical administration of prewarmed physiological saline solution and UCA, (3) scan of the urinary tract after administration of UCA, and (4) scan of the urinary tract after administration of UCA during and after voiding [28, 40]. Optionally, a transperineal US of the urethra and/or cyclical filling of the bladder may be added. Various US modalities are available for performing VUS. The main differences between the modalities are in the degree of conspicuity of the microbubbles and sensitivity of reflux detection.
US scan modalities
Colour Doppler US
The microbubbles increase the backscattered signal from the urine giving it a characteristic chromatic effect, e.g. a set of blue and red punctiform colour collection . This makes recognition of the urine flow direction easier and enhances the visualization of the microbubbles in the pelvicalyceal system. It is recommended that the Doppler US settings be optimized to perform VUS [31, 41]. Currently, there are five reports in which colour Doppler US alone or in combination with fundamental imaging have been used for VUS [11, 14, 31, 41, 42]. The diagnostic accuracy of colour Doppler US was compared with fundamental imaging in only one study . In the same group of patients VUS without and with colour Doppler US followed by VCUG was carried out. With VCUG as the reference method, the diagnostic accuracy was found to be 96% with colour Doppler US and 90% without. In another study, no significant increase was found in the sensitivity and specificity of VUS when adding colour Doppler US . In one study a modified colour Doppler US examination was used employing a high mechanical index (MI) burst contrast technique based on stimulated acoustic emission (SAE), in which the microbubbles are made to burst creating strong acoustic signals . It was possible to detect more reflux with the burst colour Doppler US compared to regular colour Doppler US or fundamental imaging and even VCUG. No systematic evaluation is available regarding the application of power Doppler US for VUS. Overall, adding optimized colour Doppler US to fundamental imaging seems to have some advantage and should be tried when other contrast-specific modalities are not available.
The nonlinear propagation property of US waves is the basis of harmonic imaging . This may be optimized to receive harmonics from either tissue or microbubbles, thus creating “tissue-specific harmonic imaging” or “contrast-specific harmonic imaging”, respectively. Some US machines only use the second harmonic for imaging (narrow band), whereas others are capable of implementing a wider range of harmonics (wide band). There may be some degree of difference in image quality between these different technical approaches, in general the latter being of higher quality.
Dedicated high-MI contrast imaging with multiple display options
Precontrast scans of the bladder, ureters and kidneys
The necessity to perform a detailed scan of the urinary tract arises when the VUS is combined with a follow-up US of the urinary tract, for example after pyelonephritis or when there is a need for comparison with the postcontrast images. The scan before contrast agent administration should be carried out in accordance with standard US of the urinary tract in the supine position (and/or the prone position), in both the transverse and longitudinal planes . Particular attention should to be paid to documentation of subtle changes in the retrovesical region, the vesicoureteric junction and any dilated ureter. The renal pelves (and/or the calyces) are imaged with maximum magnification. A scan in the supine position may suffice if adequate visualization of the renal pelves on both sides is possible, even though scanning the kidneys with the child in the prone position definitely allows better demonstration of the pelvicalyceal system. It should always be kept in mind that not performing a precontrast scan reduces the duration of the whole examination. This should be the case whenever harmonic or other dedicated contrast imaging is used.
Intravesical administration of normal saline and US contrast agent
The UCA and normal saline are administered via a transurethral catheter, but suprapubic puncture is also possible. The administration of UCA is carried out under US monitoring. The aim should be to have homogeneous strong contrast agent density of the bladder contents. Early studies advocated filling the bladder to the maximum prior to injecting the UCA [13, 28]. This makes the calculation of UCA volume to be administered easier, but has the disadvantage that low-pressure reflux may be obscured. Moreover, in neonates and infants due to repeated voiding at small bladder filling volume, there is insufficient time to administer UCA and scan the urinary tract. Increasingly, a more fractional approach to administering UCA is being practised [21, 40]. It is important to note that emptying the bladder for the sake of UCA administration is not mandatory as explained above. It is helpful to inject UCA into a bladder that is not completely empty in order to have better visualization of the microbubbles and avoid a strong dorsal acoustic shadow. Using a three-way valve it is easy to alternately administer normal saline and UCA adjusting the volume of UCA to the bladder filling volume and in the end reaching the recommended dose. The Levovist suspension should be administered slowly for two reasons: first, to minimize the destruction of the microbubbles and second, to reduce settling of the suspension at the bottom of the bladder that would create an acoustic shadow that temporarily obscures the retrovesical region . In such a case, turning the child several times from side to side hastens the homogeneous distribution of the UCA in the bladder. The administration of normal saline is continued until the child has the urge to micturate or there is the first slight sign of back pressure to the infusion or injection.
Postcontrast scan of the bladder, ureters and kidneys
The US scan after contrast agent administration is basically carried out in the same manner as that before contrast agent administration. There are minor procedural variations depending on the type of US modality utilized. The diagnosis of reflux is made when echogenic microbubbles appear in a ureter or renal pelvis. When a ureter is distinctly visible behind the bladder, the microbubbles render the echo-free lumen echogenic. When the ureter is not clearly visible as a round echo-free structure, VUR can be demonstrated if microbubbles are seen entering the vesicoureteric junction or if just behind this junction, one can depict a round echogenic spot in transverse section, which can be differentiated from its surroundings by its strong echogenicity and possibly constant movement of microbubbles . When the reflux reaches the kidney the echogenic microbubbles can be detected in the pelvicalyceal system. In a recent study by Kopac et al.  the need for UCA to demonstrate reflux was again emphasized. They compared indirect non-contrast VUS with contrast-enhanced VUS in 47 children with 93 PUUs. In the former there was no catheterization and bladder filling and any increase in renal pelvic and proximal ureteric width during voiding was considered as a sign of VUR. Compared to VUS with UCA this was found to have low diagnostic accuracy of only 59%, which is not sufficiently reliable for routine use.
Postcontrast scan of the bladder, ureters and kidneys during and after voiding
The US examination is continued during and after voiding in a similar manner as above, always scanning the right and left kidneys alternately, and also the bladder if the patient’s position allows. If cyclic filling is not planned, the catheter can be removed prior to micturition. Most children can void around a thin catheter on the examination table while lying supine, prone or on the side . Other alternatives to consider are to have the child sit on a potty and to scan the kidneys from the back. A “music potty” that signals voiding with music is helpful. In older boys the option to micturate into a urine bottle while standing and being scanned from the back may be offered. At the end the bladder is checked for residual urine.
Postcontrast scan of the urethra during voiding (urethrosonography)
The most important study comparing contrast-enhanced voiding urethrosonography and VCUG is that by Berrocal et al. . In this prospective study a total of 146 children (87 boys, 59 girls) with a mean age of 3.3 years (8 days to 14 years) were recruited. In the voiding part of VUS, primarily transperineal US of the urethra was performed. During voiding the catheter was removed. The diameters of the anterior and posterior parts of the urethra were measured at maximum dilatation during voiding. In boys the normal value was found to be 6.1 ± 0.8 mm (2.8–7.1 mm) and 6.3 ± 0.67 mm (3.7–7.2 mm), respectively. In girls the urethral diameter was 4.2 ± 1.0 mm (2.5–7.8 mm). This was the basis for evaluation of pathological changes in the urethra. In all children the US study was followed by VCUG. There were three boys with posterior urethral valves detected on US with dilated posterior urethra, reduced diameter of the anterior urethra and delay in UCA flow at the valve. Furthermore, urethral stenosis was diagnosed in two boys. Seven children were evaluated after resection of the posterior urethra valves and were found to have a normal posterior urethral diameter in the presence of dilatation of the anterior part without any flow delay. In all children these findings were confirmed on VCUG. All girls and 75 boys showed a normal urethra at both transperineal US and VCUG. Thus sensitivity and specificity were each 100%. The approximate mean duration for VUS including transperineal voiding US was 30 min. In conclusion, transperineal contrast-enhanced VUS of the urethra has not only been shown to be possible but also to be a potential adjunct to VUS in routine examinations.
Cyclical filling of the bladder
VUR is an intermittent phenomenon. Differences in presence and degree of reflux on repeated examinations have been reported in both VCUG and RNC [52, 53]. In general, cyclical filling results in an increase in reflux detection rate. Repeated filling of the bladder may be necessary when there is marked discrepancy in kidney size and/or intermittent dilatation of the ureters on US and a negative result during the initial examination. VUS has a specific advantage in this regard as it is not associated with repeated exposure to radiation. Three studies have evaluated the value of cyclical filling in VUS [54–56]. In two of the studies, two cycles of bladder filling including Levovist administration were carried out with scanning in fundamental mode [54, 55]. One study was performed in 27 patients with transplanted kidneys . This group comprised eight children (age range 12.2–18.3 years) and 19 adults (age range 19.2–54.8 years). The reflux detection rate in the first and second cycles was 17 and 16 of 27, respectively, and thus not very different, but there were significantly higher reflux grades in the second cycle. So the conclusion was that cyclical filling in VUS with fundamental imaging did not result in increased reflux detection rate. In another study with a greater number and wider spectrum of patients, exclusively children, the opposite was found. Novljan et al.  evaluated cyclical filling in 49 children (age range 1.4–15.8 years, mean 4.1 years) with 98 PUUs. A total of 35 PUUs with reflux were detected when taking both cycles into account. In the first cycle 28 of 35 and in the second 33 of 35 of the PUUs were positive. In the first cycle only just 2 of 35 refluxes (both grade II) were detected. The VUR diagnosed in the second cycle alone comprised six PUUs with grade II and one PUU with grade III reflux. Not only were 25% more refluxing units detected in the second cycle but also 50% more grade III refluxes.
Grading of reflux
Reflux grading in contrast-enhanced VUS
Microbubbles only in the ureter
Microbubbles in the renal pelvis; no significant renal pelvic dilatation
Microbubbles in the renal pelvis + significant renal pelvic dilatation + moderate calyceal dilatation
Microbubbles in the renal pelvis + significant renal pelvic dilatation + significant calyceal dilatation
Microbubbles in the renal pelvis + significant renal pelvic dilatation and calyceal dilatation + loss of renal pelvis contour + dilated tortuous ureters
Duration of VUS examination
In four comparative studies, in which VUS and VCUG were carried out successively, the duration of each procedural step was recorded [12, 28, 31, 42]. In two of the studies VUS was carried out using fundamental mode [12, 28]. The other two studies incorporated colour Doppler US [31, 42]. In these studies the durations of VUS, including catheterization, were in the range 26–34 min with the precontrast US taking up almost one-third of the time. The durations of VCUG, adding the time for catheterization, were in the range 13–20 min. In one other study VUS and VCUG were carried out simultaneously and here the duration of one such examination including catheterization was 9 min . Novljan et al.  performed VUS with cyclical filling (two fillings) and the mean duration of the VUS was 24 min (range 15–30 min). Overall, these studies show that the duration of VUS shows a wide range and is longer than that of VCUG. As mentioned above the precontrast US may not be necessary when using harmonic or other dedicated contrast imaging modalities, resulting in a reduction of the duration of VUS by almost one-third. This would put the duration of VUS equivalent to that of VCUG.
VUS with a second-generation US contrast agent (SonoVue)
In 2001 a second-generation UCA—SonoVue (Bracco, Milan, Italy)—was approved in the European Union for IV use in adults. SonoVue is now widely used, the main application being for the evaluation parenchymal abdominal lesions . Even though it has not been approved yet for use in children one in-vitro and four clinical studies point out potential advantages compared to the use of the first-generation UCA, Levovist [63–67]. SonoVue is composed of a stabilized aqueous suspension of sulphur hexafluoride (SF6) microbubbles with a phospholipid shell and is available as a package comprising one vial with granules and a 5-ml syringe prefilled with normal saline . In an in-vitro comparative study with Levovist (5% volume) the contrast duration with SonoVue was seven times longer at a dose that was 80% lower . It was found that UCA at 0.25–1.0% of the filling volume would provide adequate contrast. Moreover, the contrast duration of a freshly prepared suspension of SonoVue was stable over 6 h, whereas Levovist showed a significant reduction after 30 min.
Contraindications and adverse events from intravesical administration of US contrast agents
There are no specific contraindications as such to the intravesical administration of Levovist. There are five clinical studies including a total of 626 patients with an age range of 2 days to 20 years, in which systematic monitoring for possible adverse events related to intravesical administration of Levovist were carried out [12, 20, 28, 41, 42]. The evaluation incorporated all or some of the following: various levels of vital sign monitoring [12, 28], assessment for possible signs and symptoms during and after the procedure, observation for up to 12 h as inpatient , and request to the patient and parents to report any symptoms in the next 24 h and an active 24-h follow-up by phone. This evaluation was carried out within the context of comparative studies, in which VCUG was performed following VUS. All patients were catheterized for the examinations. There were 15 patients with transient visible haematuria during or at completion of voiding at either VUS or VCUG and one patient each with transient mild abdominal and urethral pain. For these observed adverse events the catheterization was primarily to blame rather than the UCA . No substance-specific adverse events definitely related to the intravesical administration of Levovist were observed.
The osmolality of Levovist in solution is about five times higher than that of blood . This osmolality corresponds to that of previously used ionic radiographic contrast agents, which were likewise instilled into the bladder. No adverse events attributable to the osmolality were observed with these agents. Apart from this, the amount of UCA administered is small and in the bladder there is usually urine and/or normal saline, resulting in dilution of the hyperosmolar solution. Hyperosmolality of the UCA can, therefore, be ignored in VUS, particularly as it lies approximately in the physiological range of osmolality of urine. No animal study has been published on the potential effect of insonation of the urothelium in the presence of microbubbles, particularly at high MI settings. Potential alterations of the urothelium cannot be excluded with absolute certainty. Over the last 10 years, predominantly in Europe, it is roughly estimated that some 20,000 VUS examinations have been conducted in children (publications, reports and personal communications). There have been no reports of clinical adverse effects related to the intravesical administration of Levovist.
Experience with the new UCA, SonoVue, for VUS is still very limited. Contraindications for the IV administration are known hypersensitivity to sulphur hexafluoride and certain cardiopulmonary disorders . Recently, a large-scale retrospective analysis showed that IV SonoVue has a good safety profile in abdominal applications . In the small number of VUS studies with a total of 210 children no adverse events directly related to the UCA have been reported [64–67]. There are, as yet, no detailed studies regarding any possible interaction with urine and the urothelium.
It is important to realize that a breakthrough to implement US for reflux diagnosis, which had began in the late 1970s, only came with the availability of a stable UCA. Advances in US technology resulting in marked improvement in the depiction of microbubbles have facilitated many procedural aspects in addition to the diagnostic accuracy of the modality. Furthermore, the first results of VUS with the use of a more stable second-generation UCA point to further procedural and diagnostic progress. Like VCUG and direct RNC, it is still necessary to catheterize the bladder or perform suprapubic puncture for VUS. This is a major drawback of all direct reflux examinations and one that makes them invasive. Attempts to generate bubbles exogenously using high-intensity focused US would solve this problem, but have not yet moved beyond the stage of animal studies .